Albumin–graphene oxide conjugates; carriers for anticancer drugs

Jokar, Safura; Pourjavadi, Ali; Adeli, Mohsen

doi:10.1039/c4ra05752j

Cited by 41 publications

(24 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Jokar et al reported albumin-conjugated GO onto which was loaded paclitaxel, an insoluble microtubulin stabilizer. The albumin-GO-paclitaxel complex also showed pH-dependent release of paclitaxel with 18% greater increase at pH = 5.4 compared with pH = 6.8 [16]. Xu et al reported a study using covalently conjugated PEG-GO structures for delivering paclitaxel to A549 cells and MCF-7 cells in vitro [35].…”

Section: Graphene Types Go Rgomentioning

confidence: 99%

“…This nanomaterial has attracted a great deal of attention due to some of its unique nanoscopic properties [14], and shows potential for various material and biomedical science applications [12,15]. Its scientific significance and potential transformative impact have been recognized by the 2010 Nobel Prize in Physics [16]. Recent reports also predict that graphene may overtake carbon nanotubes in commercial applications [17].…”

mentioning

confidence: 99%

See 1 more Smart Citation

Graphene-Based Platforms for Cancer Therapeutics

et al. 2016

View full text Add to dashboard Cite

Graphene is a multifunctional carbon nanomaterial and could be utilized to develop platform technologies for cancer therapies. Its surface can be covalently and noncovalently functionalized with anticancer drugs and functional groups that target cancer cells and tissue to improve treatment efficacies. Furthermore, its physicochemical properties can be harnessed to facilitate stimulus responsive therapeutics and drug delivery. This review article summarizes the recent literature specifically focused on development of graphene technologies to treat cancer. We will focus on advances at the interface of graphene based drug/gene delivery, photothermal/photodynamic therapy and combinations of these techniques. We also discuss the current understanding in cytocompatibility and biocompatibility issues related to graphene formulations and their implications pertinent to clinical cancer management.

show abstract

Section: Graphene Types Go Rgomentioning

confidence: 99%

mentioning

confidence: 99%

Graphene-Based Platforms for Cancer Therapeutics

et al. 2016

View full text Add to dashboard Cite

show abstract

“…[1][2][3] Several nanomedicines, like doxorubicin encapsulated in pegylated liposomes (Doxil) and a polymeric micelle formulation of paclitaxel (Genexol-PM) have entered the market. [1][2][3] Several nanomedicines, like doxorubicin encapsulated in pegylated liposomes (Doxil) and a polymeric micelle formulation of paclitaxel (Genexol-PM) have entered the market.…”

Section: Introductionmentioning

confidence: 99%

Comprehensive studies of pharmacokinetics and biodistribution of indocyanine green and liposomal indocyanine green by multispectral optoacoustic tomography

et al. 2015

View full text Add to dashboard Cite

Real-time and continuous monitoring of systemically administered agents is an important task in pharmaceutical development. Herein, we performed a real-time continuous study of the pharmacokinetics and biodistribution of indocyanine green (ICG) and liposomal indocyanine green (Lipo-ICG) in vivo by multispectral optoacoustic tomography (MSOT). By comparing the blood clearance and uptake behavior of these two ICG formulations in liver, spleen, kidney and tumor, we showed that Lipo-ICG prolonged the retention time of ICG in blood, and resulted in enhanced accumulation and retention in liver, spleen, and tumor. The results obtained from the MSOT test provided a comprehensive and continuous view of the metabolic behavior of the injected agents in different formulations. The results may also be helpful for understanding this new imaging technique.

show abstract

“…The conjugation of albumin onto the surface of graphene by a PEG linker leads to globular hybrid nanomaterials, which are able to transfer anticancer drugs, such as paclitaxel, both by the graphene surface and the albumin cavity. 82 4.1.2. Noncovalent interactions.…”

Section: Graphenementioning

confidence: 99%